New Name for a Global Condition
PCOS a condition impacting millions of women – A disorder that affects women’s reproductive health and elevates their diabetes risk often remains undiagnosed, yet experts believe renaming it could improve access to care. Polycystic ovarian syndrome, or PCOS, has long been associated with ovarian cysts, but the condition extends far beyond that. The World Health Organization (WHO) highlights that PCOS encompasses a range of symptoms, including irregular menstrual cycles, difficulty conceiving, and metabolic complications like type 2 diabetes and cardiovascular disease. However, its name may not fully reflect the complexity of the issue, leading to misconceptions and delayed treatment.
The Evolution of PCOS Understanding
Dr. Helena Teede, an endocrinologist and professor at Monash University, has spearheaded efforts to redefine the condition. Over her 25-year career, she encountered persistent misunderstandings, with many assuming PCOS was merely about ovarian cysts. This narrow view, she argues, contributed to missed diagnoses and improper care. The new name, proposed in a Tuesday publication in *The Lancet*, aims to address these gaps by emphasizing the metabolic and hormonal dimensions of the syndrome. It now refers to polyendocrine metabolic ovarian syndrome, or PMOS, a term designed to capture its broader impact on the body.
Dr. Andrea Dunaif, a professor at Mount Sinai’s Icahn School of Medicine, notes that the condition was initially viewed as a reproductive disorder. Early research linked it to elevated male hormone levels, which can disrupt menstrual regularity and fertility. In the 1980s, scientists discovered its connection to insulin resistance, a condition where the body struggles to respond to insulin. This revelation shifted the focus from isolated ovarian issues to a more systemic metabolic problem, with increased risks for liver disease, heart conditions, and other complications.
Why the Name Change Matters
The original name, PCOS, has been criticized for being misleading. Dr. Alla Vash-Margita, an obstetrics and gynecology expert at Yale University, explains that the term perpetuated stigma, with many patients believing they had “large cysts” when that was not the case. “By calling this condition polycystic ovary, we’re missing the big picture,” she states in a
quote
. The new name, PMOS, seeks to replace this limited perception by incorporating the term “polyendocrine,” which underscores its role as a hormonal disorder. “People with PMOS experience disruptions in the endocrine system, which can lead to widespread effects,” Teede adds, highlighting the need for a name that aligns with its multifaceted nature.
Research continues to unveil additional symptoms tied to PMOS, including sleep apnea, depression, anxiety, and body dysmorphia. These findings suggest that the syndrome affects not only reproductive health but also mental and metabolic well-being. The updated terminology is intended to foster greater awareness, ensuring the condition is recognized as a complex, long-term health issue rather than a simple ovarian condition.
A Collaborative Effort Across 14 Years
The shift to PMOS was the result of a 14-year initiative involving global collaboration. Fifty-six patient and professional organizations contributed to the effort, reflecting the condition’s significance across medical disciplines. The *Lancet* paper, which outlines the name change, emphasizes the importance of a more precise label. Rachel Morman, Chair of Verity PCOS UK, notes in a news release that this rebranding will “reframe the conversation” and demand that PMOS be treated with the seriousness it warrants.
Physicians in the gynecology field have increasingly acknowledged the condition’s complexity, but Teede argues that PMOS’ impact on multiple systems requires a more unified approach. “All kinds of medical specialties should be more aware and collaborate to effectively treat patients,” she says, underscoring the need for interdisciplinary care. The term “metabolic syndrome” has been associated with early dementia risks, and PMOS may contribute to similar long-term consequences. “What you do makes a difference,” Dunaif mentions, suggesting that the name change could lead to more comprehensive management strategies.
Challenges and Future Directions
While the new name is seen as a step forward, some experts believe it still needs refinement. Dunaif points out that the condition’s metabolic aspects extend beyond the ovaries, with family histories indicating that individuals without ovaries may also be affected. “The name might be more accurate if it broke it up into subtypes,” she suggests, such as for those primarily experiencing reproductive symptoms or those with metabolic manifestations. This idea aligns with ongoing discussions about categorizing PMOS to better reflect its diverse presentations.
Teede’s work, which led to the name change, has been instrumental in redefining the syndrome’s scope. Her research highlights the need for a label that reflects the condition’s metabolic underpinnings and its role in hormonal imbalances. “By rethinking the name, we can shift focus from the ovaries to the broader endocrine system,” she explains. This change is expected to encourage greater investment in research, improved diagnostic protocols, and more holistic treatment approaches.
The transition from PCOS to PMOS represents a significant evolution in how the condition is understood and addressed. With an estimated 10% to 13% of reproductive-age women worldwide affected, the name change aims to bridge the gap between perception and reality. Currently, about 70% of these women remain undiagnosed, but the updated terminology could help raise awareness and prompt timely interventions. As medical professionals continue to explore the syndrome’s complexities, the hope is that PMOS will become a more accurate and impactful label, guiding future care and research efforts.
Dr. Dunaif remains cautiously optimistic about the name change but acknowledges the need for further refinement. She emphasizes that the condition’s metabolic aspects are not fully encapsulated by the new term, which may still require subcategories to capture its various forms. This nuance reflects the ongoing dialogue within the medical community about how best to describe PMOS. Despite these considerations, the shift is widely viewed as a positive step toward more accurate diagnosis and treatment.
The Road Ahead for PMOS
The collaboration that led to the name change was extensive, involving researchers, patient advocates, and healthcare professionals from around the world. This collective effort highlights the syndrome’s global impact and the shared goal of improving patient outcomes. By adopting a more descriptive name, the hope is to foster a deeper understanding of the condition’s role in women’s health. “This change will ensure that PMOS is taken seriously as a multifaceted disorder,” Morman says, stressing the importance of a name that reflects its complexity.
As the medical field embraces the new terminology, the next challenge will be to integrate PMOS into clinical practice and public discourse. The broader endocrine system’s involvement means that specialties such as endocrinology, cardiology, and psychiatry must also play a role in managing the condition. This interdisciplinary approach is essential for addressing the wide range of symptoms and long-term risks associated with PMOS. With continued research and advocacy, the new name may pave the way for more targeted therapies and better health outcomes for those impacted.
